Senktide

Test Ligands Values Explained

Test Ligand ID - A unique identifier for the test ligand
Ligand Name - Name of the test ligand

Test Ligand ID1702
Ligand NameSenktide
PubMed Compound Id108147
StructureProduct Image
Molecular FormulaC40H55N7O11S
Molecular Weight842.0
SMILESCC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
SynonymsSenktide
106128-89-6
Succinyl-6-asp-8-Me-phe-substance P (6-11)
Substance P (6-11), succinyl-asp(6)-Me-phe(8)-
suc[Asp6,MePhe3]SP(6-11)
Substance P (6-11), succinyl-aspartyl(6)-methylphenylalanine(8)-
suc[Asp6,MePhe3]SP(6-11))
(3S)-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[(4-hydroxy-4-oxobutanoyl)amino]-4-oxobutanoic acid
4-10-Neuromedin B (swine spinal cord), N-(3-carboxy-1-oxopropyl)-6-(N-methyl-L-phenylalanine)-7-de-L-valine-
L-Methioninamide, N-(3-carboxy-1-oxopropyl)-L-alpha-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl-
N-(3-Carboxy-1-oxopropyl)-6-(N-methyl-L-phenylalanine)-7-de-L-valine-4-10-neuromedin B (swine spinal cord)
suc(Asp6,MePhe3)SP(6-11)
suc(Asp6,MePhe3)SP(6-11))
(3S)-4-(((2S)-1-(((2S)-1-((2-(((2S)-1-(((2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)-methylamino)-1-oxo-3-phenylpropan-2-yl)amino)-3-((4-hydroxy-4-oxobutanoyl)amino)-4-oxobutanoic acid
189261-10-7
CHEMBL106124
(5S,8S,14S,17S,20S)-14,17-Dibenzyl-5-carbamoyl-20-(carboxymethyl)-8-isobutyl-15-methyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic acid
Succinyl-(Asp6,N-Me-Phe8)-Substance P (6-11)
(3S)-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic acid
Natalizumab (anti-ITGA4)
GTPL2127
SCHEMBL5238634
DTXSID80909926
HMHYXLVEFVGOPM-QKUYTOGTSA-N
HY-P0187
BDBM50052524
CS-8091
DA-56013
DA-78081
FS109556
MS-31559
G12250
Q27088780
Suc-Asp-Phe-N-Me-Phe-Gly-Leu-Met-NH2; H-(Suc)DF(NMeF)GLM-NH2
(S)-N-((S)-1-{[(S)-1-({[(S)-1-((S)-1-Carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-phenyl-ethyl)-3-(3-carboxy-propionylamino)-succinamic acid
4-({14-Benzyl-7,10,13-trihydroxy-5-[hydroxy(imino)methyl]-15-methyl-8-(2-methylpropyl)-16-oxo-18-phenyl-2-thia-6,9,12,15-tetraazaoctadeca-6,9,12-trien-17-yl}imino)-3-[(3-carboxy-1-hydroxypropylidene)amino]-4-hydroxybutanoic acid
Created AtJan 13, 2025 2:47 pm
Updated AtJan 13, 2025 2:47 pm